A multicenter, single-arm, open-label Phase I study of AN1004 (Pelareorep) oncolytic virus plus paclitaxel inChinese patients with Hormone receptor-positive and HER2-negative advanced/metastatic breast cancer (REO 026-1)

Li, Wei et al, Previously presented at the 2022 San Antonio Breast Cancer Symposium®; December 6-10, 2022